Access cutting-edge hereditary angioedemas treatment through this clinical trial at a research site in Phoenix. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Phoenix location
Preparing your pre-screening questions…
Access hereditary angioedemas specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related hereditary angioedemas treatment provided free
Check if you qualify for this hereditary angioedemas clinical trial in Phoenix, AZ
No-Cost Study Care
Local to Phoenix
Convenient for AZ residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
This is a multinational, multicenter, prospective, observational cohort study of patients with HAE in the real-world setting. The study will include patients newly initiating garadacimab in routine clinical practice. Each participant will be followed for 48 months after index date (date of the first administration of garadacimab). Patient data will be collected from the HAE eDiary, patient medical records (MRs) and/or during a routine clinical visit and will be entered into the electronic case report form (eCRF) via an electronic data capture (EDC) system. Data pertaining to HAE attacks, prior HAE treatments, retrospective focused safety data collection, and healthcare resource utilization (HCRU) over a look-back period of 12 months prior to the enrollment will be extracted from the MR, and patients will also record retrospective HAE attack related data over a look-back period of 3 months prior to enrollment in the HAE eDiary. The primary aim of this study is to investigate the real-world effectiveness of garadacimab as measured by HAE attack rate before and after garadacimab initiation in patients with HAE over 24 months of follow-up. The study will aim to complement the data available from the clinical development program on the efficacy, safety, and health-related quality-of-life (HRQoL) in patients with HAE taking garadacimab.
Sponsor: CSL Behring
Yes, this clinical trial (NCT07001280) has an active research site in Phoenix, AZ that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for hereditary angioedemas treatment options in Phoenix, AZ, this clinical trial (NCT07001280) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Phoenix research site is actively enrolling participants for this clinical trial. You'll receive care from experienced hereditary angioedemas specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all hereditary angioedemas clinical trials near you to find additional studies recruiting in your area.
See all ankylosing spondylitis clinical trials recruiting in Phoenix — not just this study.
Browse Ankylosing Spondylitis Trials in Phoenix →